IMRX · Immuneering Corp
$4.10
+0.03 (+0.68%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$276.26M
Shares
64.70M
Volume · Oct 5
10.22K
Avg daily vol (3M)
715.19K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.07
Open$4.10
Day$4.02–4.15
52W close$3.92–8.33
Avg vol 30d657K
Short int15.6M · 24.0% float · 20.6d
Short vol57%
Last earningsJun 1, 2026
DataJul 2021–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Dec 19, 2026
Est · unconfirmed
· in 11 wks
filed Aug 5, 2026
call held Nov 12, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$57.28M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-20.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+79.8%
Year over year · more shares
Price change (1Y)
-37.7%
Trailing year
Short interest
24.0%
Latest settlement · 20.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−12%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−29%
trailing
YTD return
−38%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
24.04% of float · ▲ +4.8% MoM · 20.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+38%
Y/Y
Free cash flow
$-45.5M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
24.04% of float · ▲ +4.8% MoM · 20.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $4 · 3%
Range high $8
vs 200-day avg -19%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMRX
this stock
Immuneering Corp
|
$276.26M | -38.1% | -100.0% | — | 24.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMRX | -4.7% | -19.3% | -28.6% | -0.6% | -38.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.5% | -18.8% | -40.8% | -1.5% | -51.0% |